{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:41:39Z","timestamp":1767181299509,"version":"3.48.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"unspecified","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Knut and Alice Wallenberg Clinical Scholars programme"},{"name":"government grants under the ALF agreement","award":["ALFGBG-717971"],"award-info":[{"award-number":["ALFGBG-717971"]}]},{"name":"De Blindas V\u00e4nner grant"},{"name":"the Swedish Medical Research Council","award":["2020\u201301092"],"award-info":[{"award-number":["2020\u201301092"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Sweden has a long-standing tradition of actively managing infants born extremely preterm at 22\u201323\u2009weeks\u2019 gestational age. This study analyses screening and treatment pathways for retinopathy of prematurity (ROP) in these infants, assessing costs and health outcomes to develop a model of direct healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method and analysis<\/jats:title>\n                    <jats:p>The cohort included all 399 infants born at 22\u201323\u2009weeks in Sweden (2007\u20132018) who underwent ROP screening, recorded in the national ROP registry SWEDROP. A health economic model estimated costs based on three primary pathways: (1) no sight-saving treatment, (2) laser as initial treatment and (3) anti-vascular endothelial growth factor (anti-VEGF) as initial treatment. Pathways 2 and 3 were further divided into single and multiple treatments. Costs were calculated using screening frequency, treatment and neonatal care expenses. Register data were verified against medical records. An expanded model incorporated gestational age and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the basic model, 36% received laser (16 screenings on average; 32% required retreatment), while 7% received anti-VEGF injections (25 screenings; 69% required retreatment). The cost of screening and treating an infant with laser was Int$ 18 590, compared with Int$ 20 792 for anti-VEGF. The expanded models showed similar screening and treatment frequencies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite similar overall costs, the higher screening burden in the anti-VEGF group (25 vs 16 screenings) raises concerns regarding cost-effectiveness and potential health impacts. Main limitations include the use of cost data from a single hospital, potential selection bias between treatment groups and limited precision in small subgroups. These findings lay the groundwork for future research on long-term health and cost outcomes in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002507","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:40:17Z","timestamp":1767181217000},"page":"e002507","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Modelling direct healthcare costs for screening and treatment of retinopathy of prematurity among infants born at gestational age &lt;24 weeks: findings from a Swedish cohort"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-5164","authenticated-orcid":false,"given":"Chatarina","family":"L\u00f6fqvist","sequence":"first","affiliation":[{"name":"Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"University of Gothenburg Centre for Person-centred Care (GPCC), Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shambhavi","family":"Sharma","sequence":"additional","affiliation":[{"name":"University of Gothenburg Centre for Person-centred Care (GPCC), Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-1244","authenticated-orcid":false,"given":"Ann","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-5162","authenticated-orcid":false,"given":"Hanna","family":"Gyllensten","sequence":"additional","affiliation":[{"name":"Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"University of Gothenburg Centre for Person-centred Care (GPCC), Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2025123103401277000_10.1.e002507.1","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/apa.16753","article-title":"Preterm birth in the Nordic countries-Capacity, management and outcome in neonatal care","volume":"112","author":"Norman","year":"2023","journal-title":"Acta Paediatr"},{"key":"2025123103401277000_10.1.e002507.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208129"},{"key":"2025123103401277000_10.1.e002507.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60178-6"},{"key":"2025123103401277000_10.1.e002507.4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","article-title":"Screening Examination of Premature Infants for Retinopathy of Prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"2025123103401277000_10.1.e002507.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314874"},{"key":"2025123103401277000_10.1.e002507.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"2025123103401277000_10.1.e002507.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057864","article-title":"Costs associated with retinopathy of prematurity: a systematic review and meta-analysis","volume":"12","author":"Gyllensten","year":"2022","journal-title":"BMJ Open"},{"key":"2025123103401277000_10.1.e002507.8","doi-asserted-by":"crossref","DOI":"10.2196\/60367","article-title":"Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study","volume":"27","author":"Wu","year":"2025","journal-title":"J Med Internet Res"},{"key":"2025123103401277000_10.1.e002507.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2025123103401277000_10.1.e002507.10","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s40123-023-00744-7","article-title":"Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity","volume":"12","author":"Hartnett","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"2025123103401277000_10.1.e002507.11","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"2025123103401277000_10.1.e002507.12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/apa.16354","article-title":"National cohort of infants born before 24 gestational weeks showed increased survival rates but no improvement in neonatal morbidity","volume":"111","author":"Lundgren","year":"2022","journal-title":"Acta Paediatr"},{"key":"2025123103401277000_10.1.e002507.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055567","article-title":"Retrospective evaluation of ophthalmological and neurological outcomes for infants born before 24 weeks gestational age in a Swedish cohort","volume":"12","author":"Hellstr\u00f6m","year":"2022","journal-title":"BMJ Open"},{"key":"2025123103401277000_10.1.e002507.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"key":"2025123103401277000_10.1.e002507.15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/ijerph7041835","article-title":"Health economic assessment: cost-effectiveness thresholds and other decision criteria","volume":"7","author":"Simoens","year":"2010","journal-title":"Int J Environ Res Public Health"},{"key":"2025123103401277000_10.1.e002507.16","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10030158","article-title":"Health Economic Decision Tree Models of Diagnostics for Dummies: A Pictorial Primer","volume":"10","author":"Rautenberg","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2025123103401277000_10.1.e002507.17","first-page":"1","article-title":"Sweden: Health System Review","volume":"25","author":"Janl\u00f6v","year":"2023","journal-title":"Health Syst Transit"},{"key":"2025123103401277000_10.1.e002507.18","first-page":"130","article-title":"Decision tree methods: applications for classification and prediction","volume":"27","author":"Song","year":"2015","journal-title":"Shanghai Arch Psychiatry"},{"key":"2025123103401277000_10.1.e002507.19","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.eclinm.2024.102567","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial","volume":"71","author":"Marlow","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2025123103401277000_10.1.e002507.20","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"2025123103401277000_10.1.e002507.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/NHYK3694","article-title":"A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy","volume":"29","author":"Hodgson","year":"2025","journal-title":"Health Technol Assess"},{"key":"2025123103401277000_10.1.e002507.22","unstructured":"Ekonomi- och verksamhetsstatistik inom h\u00e4lso- och sjukv\u00e5rden [Economic and operational statistics in the health care sector]. Available: https:\/\/skr.se\/skr\/halsasjukvard\/ekonomiavgifter\/ekonomiochverksamhetsstatistik.46542.html [Accessed 25 Jun 2025]."},{"key":"2025123103401277000_10.1.e002507.23","unstructured":"Landstingsprisindex, LPI, och prisindex med kvalitetsjusterade l\u00f6ner f\u00f6r regioner, LPIK [County Council Price Index (LPI) and the Price Index with Quality-Adjusted Wages for Regions (LPIK)]. Available: https:\/\/skr.se\/skr\/ekonomijuridik\/ekonomi\/prognoserplaneringbudget\/prisindex\/lpilpik.1332.html [Accessed 01 Jul 2025]."},{"key":"2025123103401277000_10.1.e002507.24","unstructured":"Purchasing power parities (PPP). OECD. Available: https:\/\/www.oecd.org\/en\/data\/indicators\/purchasing-power-parities-ppp.html [Accessed 01 Jun 2025]."},{"key":"2025123103401277000_10.1.e002507.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.021"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:40:23Z","timestamp":1767181223000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjophth-2025-002507"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002507","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}